• Loss of $3.57 million for the half-year period
• Received $1.65 million in grant income
• Recorded $1.69 million in R&D tax rebate
• Increased research and development costs to $6.16 million

EMVision Medical Devices Ltd reported a loss of $3.57 million for the half-year ended 31 December 2024, compared to a loss of $112,607 in the previous corresponding period. The increase in loss was largely due to higher research and development costs associated with the company's ongoing clinical trial activities, including device manufacturing, contractor and site costs. During the half-year, the company received $1.64 million in grant income from the Australian Stroke Alliance Limited and the Modern Manufacturing Initiative Medical Products Manufacturing Translation Stream, as well as $1.69 million in R&D tax rebate. Operating expenses during the half-year principally related to research and development costs associated with the EMVision Technology, employee expenses, general corporate overheads, and non-cash share-based payments. The company had a net asset position of $15.41 million at 31 December 2024, including cash of $13.61 million and borrowings of $2.62 million from the NSW Medical Devices Fund. Developing and commercialising new medical devices presents both exciting opportunities and risks, which EMVision mitigates by employing experts and adhering to high standards and approvals required for medical device development and clinical trials.